Shin Nippon Biomedical Laboratories has announced results from a Phase 1 study of its intranasal zolmitriptan formulation (TRZ) for the treatment of migraine headaches. The company is developing several intranasal drugs based on its μco muco-adhesive powder carrier system and intranasal powder delivery device.
According to SNBL, the study, which compared three doses of TRZ (0.75, 1.5 and 3.0 mg) to a currently marketed zolmitriptan nasal spray (5 mg) and a marketed zolmitriptan tablet (5 mg) in 16 adult volunteers, found that the concentration of zolmitriptan reached its maximum at 20 minutes after administration for TRZ compared to 120 minutes for the other nasal spray and the tablet and was well tolerated. The relative bioavailability of TRZ was 136% compared with the tablet and 182% compared with the other nasal spray.
Read the SNBL press release.
